# IMPACT BIOMEDICAL INC.

IMPACT BIOMEDICAL INC. is a public company.

## Company overview

- **Legal name:** IMPACT BIOMEDICAL INC.
- **Classification:** Public company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Incorporated in:** NV
- **Fiscal year end:** December 31
- **SEC CIK:** 0001834105

## About

Impact Biomedical develops and licenses science and intellectual property for healthcare and wellness applications. Its business model uses licensing, co-development, joint ventures and other partnerships, with potential milestone and royalty payments tied to commercialization by partners. Research programs and prospective products remain distinct from regulatory approvals or completed commercialization. A September 16, 2026 disclosure described a proposed Zoar transaction rather than a completed acquisition. For fiscal 2025, ended 2025-12-31, its originally reported results included revenue of USD 32,000; a net loss of USD 11,838,000; cash used in operations of USD 1,890,000. At that year-end, it reported total assets of USD 17,405,000 and cash and cash equivalents of USD 3,000. Historical figures retain the originally filed amounts where later comparative figures differ.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-12-31)

- **Revenue:** $32,000 (USD 32,000)
- **Net income:** -$11.8M (USD -11,838,000)
- **Total assets:** $17.4M (USD 17,405,000)
- **Cash and equivalents:** $3,000 (USD 3,000)
- **Operating cash flow:** -$1.9M (USD -1,890,000)

### FY2024 (period ended 2024-12-31)

- **Net income:** -$24.7M (USD -24,708,000)
- **Total assets:** $20.3M (USD 20,290,000)
- **Cash and equivalents:** $2.0M (USD 1,999,000)
- **Operating cash flow:** -$3.9M (USD -3,919,000)
- **Later filings:** Operating cash flow: shown as originally filed; later filings report different values for the same periods.

### FY2023 (period ended 2023-12-31)

- **Net income:** -$4.4M (USD -4,407,000)
- **Total assets:** $44.6M (USD 44,633,000)
- **Cash and equivalents:** $1,000 (USD 1,000)
- **Operating cash flow:** -$2.9M (USD -2,851,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2026-10-09 — period 2026-09-23 — 8-K
- Form 8-K — filed 2026-09-17 — period 2026-09-16 — 8-K
- Form 8-K — filed 2026-09-15 — period 2026-09-14 — 8-K
- Form 10-Q — filed 2026-08-07 — period 2026-06-30 — 10-Q
- Form 10-Q — filed 2026-05-12 — period 2026-03-31 — 10-Q
- Form 10-K — filed 2026-03-11 — period 2025-12-31 — 10-K
- Form 8-K — filed 2026-03-04 — period 2026-02-27 — 8-K
- Form 10-Q — filed 2025-11-07 — period 2025-09-30 — 10-Q
- Form 8-K — filed 2025-11-06 — period 2025-11-05 — 8-K
- Form 8-K — filed 2025-10-27 — period 2025-10-24 — 8-K
- Form DEF 14A — filed 2025-09-22 — period 2025-09-22 — DEF 14A
- Form 10-Q — filed 2025-08-14 — period 2025-06-30 — 10-Q

---

Updated: 2026-10-15T21:34:01.423Z

Canonical page: https://altss.com/profile/impact-biomedical-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology